ASMB
Assembly Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$36.60
+1.30%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 74.8M | 72.3M | 28.5M | 7.2M | — |
| Cost of Revenue | 16.7M | 129.0K | 55.9M | 48.9M | 69.1M |
| Gross Profit | 58.2M | 72.2M | (27.4M) | (41.7M) | (69.1M) |
| Operating Expenses | |||||
| R&D Expense | 63.7M | 64.8M | 55.9M | 48.9M | 70.0M |
| SG&A Expense | 20.0M | 19.6M | 18.0M | 22.9M | 23.9M |
| General & Admin Expense | 20.0M | 19.6M | 18.0M | 22.9M | 23.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (16.6M) | — | (55.9M) | (48.9M) | (68.9M) |
| Total Operating Expenses | 67.0M | 84.4M | 18.0M | 22.9M | 25.0M |
| Cost and Expenses | 83.6M | 84.4M | 73.9M | 71.8M | 94.1M |
| Operating Income (EBIT) | (8.8M) | (12.1M) | (45.4M) | (64.6M) | (94.1M) |
| Non-Operating | |||||
| Interest Income | 8.8M | 6.0M | 5.6M | 3.5M | 1.0M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 8.8M | 6.0M | 5.6M | 3.5M | 1.0M |
| Other Non-Op Income/Expense | 8.8M | 6.0M | 5.6M | 3.5M | 1.0M |
| Non-Operating Income (excl Interest) | (8.8M) | (6.0M) | (5.6M) | (3.5M) | (1.1M) |
| EBT (Pre-Tax Income) | (42.0K) | (6.1M) | (39.8M) | (61.2M) | (93.1M) |
| Income Tax Expense | — | — | 330.0K | 33.0K | — |
| Bottom Line | |||||
| Net Income | (42.0K) | (6.1M) | (40.2M) | (61.2M) | (93.1M) |
| Earnings from Cont. Ops | (42.0K) | (6.1M) | (40.2M) | (61.2M) | (93.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (42.0K) | (6.1M) | (40.2M) | (61.2M) | (93.1M) |
| Per Share | |||||
| Basic EPS | $0.55 | ($0.55) | ($6.69) | ($13.38) | ($22.82) |
| Diluted EPS | $0.55 | ($0.55) | ($6.69) | ($13.38) | ($22.82) |
| Revenue Per Share | $3.97 | $6.45 | $4.75 | $1.56 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 18.9M | 11.2M | 6.0M | 4.6M | 4.0M |
| Diluted Shares Outstanding | 18.9M | 11.2M | 6.0M | 4.6M | 4.0M |
| Profitability Metrics | |||||
| EBITDA | 68.0K | (6.0M) | (39.7M) | (60.7M) | (92.5M) |
| D&A | 110.0K | 129.0K | 129.0K | 450.0K | 498.0K |
| EBIT | (42.0K) | (6.1M) | (39.8M) | (61.2M) | (93.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026